Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers won FDA approval for Sotyktu in active psoriatic arthritis, expanding its oral immunology franchise despite a slight after-hours stock dip.
